[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100324386":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":66,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":19,"enrollmentInfo":83,"targetDuration":19,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":19,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[C-11]PiB-PET\u002FMRI","EXPERIMENTAL","All participants in this study will undergo an amyloid-PET imaging using the tracer \\[C-11\\]PiB with a simultaneous PET\u002FMRI system. The \\[C-11\\]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET\u002FMRI imaging time is approximately 60 min.",[13],"Drug: [C-11]PiB-PET\u002FMRI",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","All study participants will undergo brain imaging with \\[C-11\\]PiB-PET\u002FMRI. \\[C-11\\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Jonathan McConathy, MD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Chinara Dosse","CONTACT","(205) 975-7017","cdosse@uabmc.edu",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Evan Hudson","205-934-6499","evanhudson@uabmc.edu",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of Alabama at Birmingham Medical Center","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-86.80249,33.52066,{"lat":47,"lon":46},[50,53,55,58,60,62,64],{"name":22,"role":27,"phone":51,"phoneExt":19,"email":52},"205-996-7115","jmcconathy@uabmc.edu",{"name":54,"role":23,"phone":19,"phoneExt":19,"email":19},"Jonathan McConathy, MD, PhD",{"name":56,"role":57,"phone":19,"phoneExt":19,"email":19},"Geldmacher David, MD","SUB_INVESTIGATOR",{"name":59,"role":57,"phone":19,"phoneExt":19,"email":19},"Lapi Suzanne, PhD",{"name":61,"role":57,"phone":19,"phoneExt":19,"email":19},"Jeffers Charlotte Denise, RPh",{"name":63,"role":57,"phone":19,"phoneExt":19,"email":19},"Natelson Marissa, MD",{"name":65,"role":57,"phone":19,"phoneExt":19,"email":19},"Roberson Erik, MD, PhD",{"type":23,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Deepak Prabataram Kalbi","Assistant Professor",[70],{"name":71,"class":72},"National Institute on Aging (NIA)","NIH","100324386","phase-2-uab-alzheimers-disease-center-core-cohort---imaging-substudy-100324386",false,"NCT03503331","UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy","PiB ADC","Inclusion Criteria:\n\n\\- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).\n\n2\\. Negative urine or serum B-hCG test within 2 days of \\[C-11\\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.\n\nExclusion Criteria:\n\n1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).\n2. Inability or contraindication for undergoing MRI and\u002For PET imaging\n3. Inability to participate in the imaging studies due to severity of dementia",true,"ALL","50 Years",{"count":84,"type":85},160,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \\[C-11\\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \\[C-11\\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.",[91],"Alzheimer Disease","2026-08-10",{"date":94,"type":95},"2026-08-12","ACTUAL",{"date":97,"type":95},"2018-04-20",{"date":99,"type":85},"2028-10",{"name":5,"class":6},1]